Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
Clinical trial NCT05283226 · RECRUITING
Trial details
- NCT number
- NCT05283226
- Sponsor
- NATCO Pharma Ltd.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-30
- Primary completion
- 2026-12-30
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.